Author | Adam Brufsky, MD, PhD

October 31, 2018

Dr. Adam Brufsky speaks with Cancer Network about the evolution and future of HER2-targeted therapy.

January 15, 2015

We know that bisphosphonates prevent or delay skeletal-related events in breast cancer metastatic to bone, prevent or treat bone loss in patients receiving adjuvant aromatase inhibitor therapy, and decrease bone recurrences and breast cancer–related deaths when used in the adjuvant setting in postmenopausal women with early-stage breast cancer.